Deal Details
Follow-On Offering
Summary
Baird served as co-manager on this offering.
About
Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) recently completed a follow-on offering of 5,479,750 shares of common stock at $21.00 per share, generating gross proceeds of approximately $115.1 million. The Company intends to use the net proceeds from the offering for general corporate purposes. Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness. The Company’s pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), the Company’s first commercial product, is a once-daily dual-mechanism antibiotic approved in the United States, Europe and certain other countries for certain difficult-to-treat infections. Theravance Biopharma’s United States operating subsidiary is located in San Francisco, California.For additional information about this transaction, please contact:
- Date
- June 2016
- Company
- Theravance Biopharma, Inc.
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
- Acquiror Geography
- North America
Share
